Evidence map›Paper›PMID 34526099›Full record

ArticleJournal of hematology & oncology2021

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.

Xiao-Hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-Lie Jiang, Ming Jiang, Yong-Rong Lai, Dai-Hong Liu, Qi-Fa Liu, Ting Liu and 10 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed, 6 pooled it
30.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

179 citing papers in PubMed, 6 syntheses or guidelines pooled it, 299 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

119 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Jing ChenShanghai Children's Medical Center, Shanghai, China.
Ming-Zhe HanInstitute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Hematologic Disease, Tianjin, China.
He HuangFirst Affiliated Hospital of Zhejiang University, Hangzhou, China.
Er-Lie JiangInstitute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Hematologic Disease, Tianjin, China.
Ming JiangThe First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yong-Rong LaiThe First Affiliated Hospital of Guangxi Medical University, Guilin, China.
Dai-Hong LiuGeneral Hospital of PLA (People's Liberation Army of China), Beijing, China.
Qi-Fa LiuNanfang Hospital of Southern Medical University, Guangzhou, China.
Ting LiuWest China Hospital, Sichuan University, Chengdu, China.
Han-Yun RenPeking University First Hospital, Beijing, China.
Yong-Ping SongAffiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Zi-Min SunThe First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Xiao-Wen TangThe First Affiliated Hospital of Soochow Hospital, National Clinical Research Center for Hematologic Disease, Suzhou, China.
Jian-Min WangChanghai Hospital of Shanghai, Naval Medical University, Shanghai, China.
De-Pei WuThe First Affiliated Hospital of Soochow Hospital, National Clinical Research Center for Hematologic Disease, Suzhou, China.
Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Xi ZhangXinqiao Hospital, Army Military Medical University, Chongqing, China.
Dao-Bin ZhouPeking Union Medical College Hospital, Beijing, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China. xjhrm@medmail.com.cn.ORCID http://orcid.org/0000-0002-2145-6643
Peking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSoochow University · CNFirst Affiliated Hospital Zhejiang University · CNGuangxi Medical University · CNNanfang Hospital · CNSecond Military Medical University · CNShanghai Children's Medical Center · CNSichuan University · CNUniversity of Science and Technology of China · CNXinjiang Medical University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HSCT in China and progressive integration with the world. There have been new developments since the initial publication. To integrate recent developments and further improve the consensus, a panel of experts from the CSH recently updated the consensus recommendations, which are summarized as follows: (1) there is a new algorithm for selecting appropriate donors for allo-HSCT candidates. Haploidentical donors (HIDs) are the preferred donor choice over matched sibling donors (MSDs) for patients with high-risk leukemia or elderly patients with young offspring donors in experienced centers. This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.

Indexed as

ChinaDonor SelectionHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaSocieties, MedicalTransplantation ConditioningTransplantation, HomologousAllogeneic hematopoietic transplantationChinaConditioning regimenConsensusDonor selectionIndication

Identifiers

PMID34526099
PMCPMC8441240
OpenAlexW3200019819

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.